Tumor infiltrating lymphocyte (TIL) adoptive cell therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Tumor infiltrating lymphocyte (TIL) adoptive cell therapy, covering 2026-04-24 to 2026-04-24. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab [Phase 2]